de MaturanaRLWillshawAKuntzschARudolphRDonnellyD
A: Gastrointestinal discomfort stands as the dominant adverse response of GLP-1 agonists, including mild nausea, transient vomiting, bloating, diarrhea or constipation, which mostly emerge within the initial 28 weeks of administration as the gastrointestinal tract adapts to delayed emptying effects
These areas not only look and feel unpleasant, but they also severely impair the absorption of the peptide
Bartolome, A., Zhu, C., Sussel, L
These non-transdermal patches aim to improve skin appearance and promote relaxation without the use of drugs or stimulants
While it is naturally occurring in the human body, its application in topical products is subject to rigorous standards to ensure consumer safety and product efficacy